SCHEMBL3269520

SCHEMBL3269520

O=Cc1c(Br)ccc2cc(F)cc(F)c12

nearest known ligand 0.37

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 5/20 0.35
AGTR1 P30556 1/20 0.30
AR P10275 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3272039 0.79 ERN1 (0.35) ERN1
SCHEMBL3268821 0.76 ERN1 (0.35) ERN1
SCHEMBL3268272 0.76 ESR1 (0.35) ERN1
SCHEMBL3268022 0.75 ERN1 (0.47) ERN1
SCHEMBL3267632 0.75 ERN1 (0.35) ERN1AR
SCHEMBL3269229 0.73 MEN1 (0.41) ERN1
SCHEMBL3268893 0.73 ERN1 (0.41) ERN1
SCHEMBL29921076 0.72 ERN1 (0.42) ERN1AGTR1
SCHEMBL6556132 0.72 ERN1 (0.42) ERN1AGTR1
SCHEMBL1726007 0.69 ERN1 (0.37) ERN1AGTR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1914229-B1 NOVEL CERCOSPORAMIDE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2010-06-16 EP disclosed
US-20090036492-A1 Novel Cercosporamide Derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-02-05 US disclosed
EP-1914229-A1 NOVEL CERCOSPORAMIDE DERIVATIVE Daiichi Sankyo Company, Limited (JP) 2008-04-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090036492-A1 Novel Cercosporamide Derivative GPR119, CBR3, SLC5A2 ERN1 337/4885AGTR1 113/4885AR 3758/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.